首页> 外文期刊>European journal of ophthalmology >Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy.
【24h】

Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy.

机译:玻璃体内贝伐单抗用于继发于中心性浆液性脉络膜视网膜病变的激光光凝继发的脉络膜新生血管形成。

获取原文
获取原文并翻译 | 示例
       

摘要

Choroidal neovascularization (CNV) is a rare complication after laser photocoagulation for disorders such as central serous chorioretinopathy (CSC).We report 2 patients who developed CNV after laser treatment for persistent CSC and were treated by 3 1.25-mg intravitreal injections of bevacizumab in 1-month intervals.In both patients, best-corrected visual acuity improved from 20/120 to 20/80 and from counting fingers at 3 feet to 20/100 over 12 months of follow-up.The favorable outcome suggests that intravitreal injection of bevacizumab may be beneficial for patients who develop CNV after laser photocoagulation. The favorable outcome may be related to the limited pathology.
机译:脉络膜新生血管形成(CNV)是激光光凝治疗中枢性浆液性脉络膜视网膜病变(CSC)等疾病后的罕见并发症。我们报道2例在接受持续CSC激光治疗后发展为CNV的患者,其中3例接受1.25 mg贝伐单抗玻璃体内注射在两个月的随访中,这两名患者的最佳矫正视力从20/120提高至20/80,从3英尺的手指计数提高至20/100,良好的结果表明玻璃体内注射贝伐单抗对于激光光凝后出现CNV的患者可能有益。有利的结果可能与有限的病理学有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号